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ABSTRACT 
EL-KAHLOUT, REHAM, A., Masters of Science: June: 2017, Biomedical Sciences 
Title: Seroprevelance of Anti-MERS-CoV IgG Among Two Groups of Qatar Population: Blood 
Donors and Case Contacts 
Supervisor of Thesis: Dr. Marwan, A., Abu-Madi. 
Since its first isolation in September 2012, Middle East respiratory syndrome 
coronavirus (MERS-CoV) has diffused across 27 countries infecting more than 1910 
individuals with a high case fatality rate. However, MERS-CoV has also been reported to 
be asymptomatic or to cause influenza-like mild illnesses . In the absence of clear 
epidemiological view, cross-sectional MERS-CoV antibody surveillances in human 
populations are of global concern . In this study, we present a comparative serological 
screening of 4719 blood donors, 135 baseline case contacts and 4 MERS-CoV confirmed 
patients for the presence of anti-MERS-CoV IgG. Methods: Samples were initially 
screened using MERS-CoV recombinant spike protein Enzyme linked immunoassay 
(rELISA) from Euroimmune, Germany. To confirm rELISA results, farther serological 
testing has been performed for borderline and reactive anti-MERS-CoV IgG samples by 
indirect immunofluorescent test (full virus IIFT) IgG/M, recombinant spike protein 
indirect immunofluorescent assay IgG (rIIFA) and pseudovirus neutralizing assay 
(ppNT). To access cross reactivity, borderline and reactive samples were also tested for 
presence of IgG to other human coronaviruses (HCoV) using IIFT, rIIFA and/ or in house 
rELISA. Results: rELISA yielded 3 borderlines (all donors) and 12 reactive (7 donors, 1 
case contact and 4 samples collected from 3 MERS-CoV confirmed patients) anti-MERS-
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CoV IgG results. However, IIFT IgG confirmed only 5 reactive rELISA results (2 blood 
donors and 3 patients; the reactive case contact was not sufficient to be tested by IIFT 
IgG). Yet, r-IIFA and ppNT only confirmed the presence of specific anti-MERS-CoV 
antibodies in patients’ samples. Interestingly, all borderline and reactive tested samples 
showed reactive titers against recombinant spike proteins of other HCoV. Conclusion: 
Our findings suggest that MERS-CoV is not heavily circulated among the population of 
Qatar. This study provides an insight about the epidemiological view for MERS-CoV in 
Qatar population. It also provides a performance evaluation for the available serologic 
tests for MERS-CoV in a view of serologic status to other human coronaviruses.  
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CHAPTER 1: INTRODUCTION 
Middle East respiratory syndrome coronavirus (MERS-CoV), originally called 
“Novel Coronavirus”, is a human coronavirus (HCoV) identified in 2012 (1). It is 
responsible to cause severe acute respiratory syndrome cases and case clusters across the 
Arabian Peninsula (2) . Exported infections are linked to countries in the Middle East. 
Majority of the cases acquired the infection in the Middle East, and then exported abroad 
(2). To date, approximately more than 1,910 laboratory-confirmed cases have been 
identified with more than 680 fatalities (3). MERS-CoV–specific antibodies are widely 
found in dromedaries (Camelus dromedarius) (4-7) along with viral shedding of similar 
viruses detected in human at same region suggesting that MERS-CoV epidemiology may 
be centrally ruled by Camel (8-10). Though serological surveys are widely spread to 
explore the role of Dromedary Camels in MERS-CoV transmission (11), studies of the 
viral distribution among human population are infrequent (8, 11).  
The uncertain epidemiology stresses the need for cross-sectional surveillance of 
anti-MERS specific antibodies among human populations (12). Representative serological 
surveillances provide data to evaluate antibodies prevalence to a novel pathogen in a 
population.  This estimation plays a vital role toward a better understanding of the extent 
of  novel viral infection in a population (13). As infection with MERS-CoV continues to 
evolve, a matter of best infection control and management will arise, and studies to better 
define its prevalence are needed for the reason that infection control and management 
recommendations might be reviewed & updated as additional data become available (14, 
15).  
Due to the uncertain epidemiological view of MER-CoV among Qatar population 
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-in particular-, we designed a staged serologic surveillance study for MERS-CoV among 2 
groups of Qatar population (blood donors and case contacts) in the period of 2012-2016. 
Surveillance started with initial screening for the presence of anti-MERS-CoV IgG 
followed by confirmation and evaluation of reactive samples in view of other human 
coronaviruses. 
Hypothesis 
Seroprevalence of anti-MERS-CoV IgG among healthy individual could be high as those 
of high risk group. 
Objectives 
We conduct serological studies that are designed to collect data to evaluate the 
seroprevalence of anti-MERS-CoV IgG in two groups of Qatar population (i) high risk 
group: those in close contact with confirmed patients, (ii) low risk group: normal healthy 
population. Eventually the long-term objective is to provide insight into a better 
understanding of the epidemiology of the disease and the risk of infection in the 
population of Qatar.  
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CHAPTER 2: BACKGROUND 
 
 Coronaviruses comprise a large family of enveloped RNA viruses (Figure 
1) that have the potential to infect wide spectrum of animals and human (16). 
Coronaviruses Infections may range from the common cold to severe acute respiratory 
syndrome (SARS) (16). Various  novel strains have been evolved or recognized in animal 
and human in the last decade (17). The most two recent coronavirus emergence incidence 
in the  twenty-first century include the extremely pathogenic severe acute respiratory 
syndrome coronavirus (SARS-CoV) (18) and MERS-CoV (1)  strains that cause notable 
mortality and morbidity in affected individuals, particularly the elderly patients (19, 20). 
Human Coronaviruses 
In 1960s two coronaviruses (HCoV-229E and HCoV-OC43) were identified as 
potential human pathogens (Figure 2) causing relatively mild common colds with a 
potential of more severe symptoms in immunocompromised, elderly and infants (21-31). 
However, in 2003 (Figure 2), worldwide Severe Acute Respiratory Syndrome 
coronavirus (SARS-CoV) epidemic were developed resulted in 8,000 cases with almost 
800 deaths. It was initially originated in Guangdong Province, China.  (17, 32-35). Further 
investigations denoted that this virus have passed to humans from zoonotic origin i.e. bats 
(Rhinolophus: horseshoe bats) (36), raccoon dogs (Nyctereutes procyonoides) and 
Himalayan palm civets (Paguma larvata) (37, 38). Finally, global public health control and 
extensive containment efforts break this epidemic (33, 39). 
Following SARS-CoV epidemic, more two coronaviruses strains (HCoV-NL63 
and HCoV-HKU-1) with potential pathogenicity to humans, were recognized (Figure 2) 
from archived respiratory samples (40-42). The two viruses were result in mild to severe 
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lower respiratory tract illnesses. However, the prevalence and severity of the disease 
particularly in the very young are not yet fully covered (43). Despite that the identification 
of HCoV-NL63 and HCoV-HKU-1 was covered recently, molecular clock analyses show 
that HCoV-NL63 may evolved from HCoV-229E "closest relative", about 500–800 years 
back; however, such estimated periods of time could be, greatly under or overvalued due 
to mutation masking and purifying selection rate changes as with all other molecular clock 
analyses (44-46).
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Figure 1. International Coronaviridae taxonomy. Courtesy of G. Whittaker and R. Collins, Cornell University. Adapted from Chan et al. 2015 
(47). 
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 Figure 2. Human Coronaviruses Classification and TimeLine of Identification.  α (Alpha), β (Beta):   phylogenetic groups; 1b, 2a,2b and 2c: 
subgroups.
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MERS-CoV  
Emergence 
The library of known coronaviruses has been greatly expanded following bat 
reservoir searching of SARS-CoV. Coronaviruses are found in various animal species 
including different bats, birds, whales, dogs, mice, pigs, cats and horses (48). Moreover, 
several animal coronaviruses have similar phylogenetic with known pathogenic human 
coronaviruses (36, 49-57). Such findings suggest the highly potential for new 
coronaviruses emergence. This was approved by the emergence of a novel strain, defined 
as middle east respiratory syndrome coronavirus (MERS-CoV) (17). 
In April 2012, The Health Ministry of Jordan has reported an outbreak of unknown 
origin of severe lower respiratory tract infection in an intensive care unit of a public 
hospital in Zarqa city (58). The outbreak formed of 11 cases including 10 health care 
workers (58, 59). No etiological source could be identified after epidemiological 
surveillance along with laboratory testing performed immediately following the outbreak. 
(58).  
Around June-mid 2012, a 60-year old Saudi man had been admitted to a private 
hospital in Jeddah, Saudi Arabia, presented with severe respiratory illnesses that rapidly 
progressed to acute pneumonia and renal failure followed by death.(1, 60). During 
hospitalization time, his sputum sample along with infected cell cultures tested negative 
against known antibodies of a group of commonly known respiratory viral pathogens 
(influenza A and B, parainfluenza viruses’ types 1 to 3, respiratory syncytial virus, and 
adenovirus). However, suggestion of virus replication has been indicated from cytopathic 
changes for a sputum sample obtained on admission, inoculated in LLC-MK2 and Vero 
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cells (1). Ten to eleven days following his admission, his serum samples reacted strongly 
for immunofluorescence assay specific for IgG antibody at dilutions of 1:20. In contrast 
around 2400 control serum samples collected from 2010 through 2012 from individual 
referred to the same Hospital tested negative in this analysis. This contrast suggested that 
the patient had developed antibodies to an unknown virus that were not recognized in the 
public through the past 2 years (1). Further Real-time PCR assay on nucleic acids extracted 
from the patient inoculated cell-culture supernatants resulted negative for enterovirus, 
human metapneumovirus, and human herpesvirus types 1 to 3 (1).The patient had died 
elven days following his admission. However, attempts were continued to identify 
causative pathogen. At the mid of July, wide spectrum PCR assays of all known 
paramyxoviruses also resulted negative. Later, a positive result had been yielded from 
family-wide real time PCR assays for broad-spectrum "pan-coronavirus", but it was not 
SARS-CoV. As consequence, patients sample has been sent to Erasmus Medical Centre 
(EMC) in The Netherlands and a novel coronavirus was firstly identified and initially called 
"human coronavirus-EMC/2012" (61). 
In 22-9-2012, three months following the admission of the above-mentioned patient 
in Jeddah, a second infected case with the same virus has been reported from 49-year old 
Qatari man with a previous traveling history to Saudi Arabia. He was transferred from the 
intensive care unit (ICU) in Qatar and was diagnosed and treated in the United Kingdom 
(62). 
Following the identification and reporting of the novel coronavirus (MERS-CoV), 
The Health Ministry of Jordan shipped the stored samples of the previous reported lower 
respiratory tract infection outbreak to United States Naval Medical Research Unit-3 (US 
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NAMRU-3) in Cairo. A total of 2 MERS-CoV laboratory-confirmed and 11 probable cases 
were identified from this outbreak of whom 10 were health care workers and 2 were family 
members of cases  (58).  
Since then, Subsequent cases and clusters of infections continue, particularly in 
Saudi Arabia (63). 
Epidemiology & Geographic Distribution 
  
Since April 2012, more than 1910 laboratory-confirmed cases of infection with 
MERS-CoV have been reported from 27 countries (Table.1) including more than 650 
deaths (crude Case Fatality Rate (CFR) 35% )(3, 20).Cases have been reported primarily 
from Arabian Peninsula with the majority of cases from Saudi Arabia (about 80%), 
including clusters. Moreover, cases reported from countries outside of the Arabian 
Peninsula, have noted either a history of traveling to Arabian Peninsula or a close contact 
to MERS-CoV infected patients (20).  
The reported MERS cases of the Middle East showed a small increasing of the cases 
during March and April 2013. However, it increased dramatically in March and April 2014 
followed by sharped declined in mid-May 2014 (20). In May and June 2015, an outbreak 
of more than 180 cases reported in South Korea; the index case had a recent traveled to 
different countries in the Arabian Peninsula (64, 65). 
The median age among laboratory-confirmed cases is 52 and 65.6% of cases are 
male (20). About 48% of laboratory-confirmed cases were reported with severe illnesses 
or death, while 19.9% had moderate symptoms. However, 20.6% of cases had no or mild 
symptoms. About 20% of cases were reported among health care workers (20).  
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Table 1 
 
Number of Laboratory-confirmed MERS-CoV Cases Reported by Countries/ Year (2012 - 
Dec.2016). Exported From WHO (20). 
 
 
Country  Number of Reported Laboratory Confirmed MERS-CoV Cases 
Algeria   2 
Austria   2 
Bahrain   1 
China   1 
Egypt   1 
France   2 
Germany   3 
Greece  1 
 Iran   6 
Italy   1 
Jordan   28 
Kuwait   4 
Lebanon   1 
Malaysia  1 
Netherlands   2 
Oman   7 
Philippines   2 
Qatar   16 
Republic of Korea   185 
Saudi Arabia   1482 
Thailand   3 
Tunisia  3 
Turkey  1 
United Kingdom  4 
United Arab Emirates  79 
United States of 
America 
 2 
Yemen  1 
Total  1841 
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Overview of MERS-CoV Status in Qatar 
The second identified case with MERS-CoV infection has been reported in 
September 22nd, 2012 from 49-year old Qatari man with a previous traveling history to 
Saudi Arabia. He was diagnosed and treated in the United Kingdom (62). Since then, 
several cases have been reported from Qatar with a total of 20 cases up to April 2017 
including 2 deaths (Table 2).   
The Ministry of Health along with the Ministry of Environment in Qatar in 
collaboration with international support investigated the slaughterhouse, linked to two 
previous MERS cases in Qatar (case # 6 & 7, Table 2) for the circulation rate of MERS-
CoV in dromedaries (66, 67). This investigation indicated that a high rate of dromedaries 
shed MERS-CoV RNA at slaughterhouse with a multiple MERS-CoV variants reflecting 
introductions of multiple viruses among trade of new animals and a rich site for MERS-
CoV circulation with a high-risk for human exposure (66). This exposure risk has been 
assessed in a compensative study by serological investigation for individuals in Qatar with 
and without daily occupational exposure to dromedaries (8). The study reported the 
detection of MERS-CoV neutralizing antibodies in healthy individuals with daily 
occupational dromedaries contact but not in whom without camel contact (8). Those 
MERS-CoV–seropositive individuals did not report severe illnesses, suggesting a potential 
of frequent unrecognized human infections (8). That’s could reflect an overestimated death 
rate of 37.1% associated with MERS-CoV infection (8). However, only few reports are 
available for the presence of MERS-CoV antibodies among a general population or specific 
groups with a major concern of the potential contribution from asymptomatic cases to the 
MERS-CoV transmission (8, 12).
12 
 
Table 2 
 
List of reported confirmed MERS-CoV infection-Qatar (67). 
 
Case Serial    SEX Age Nationality Month/ Year   Exposure/ Travel history/ Camel Contact Mortality Status 
1 Male 49 Qatari Sep.2012 Travel history to Saudi Arabia   No reported Death 
2    Nov.2012  No reported Death 
3 & 4 
Male 
Male 
59 
29 
 Aug.2013 
Travel history to Medina, Saudi Arabia 6 days before illness onset 
No reported Death 
5 Female 56  Aug.2013  
Died 13 days following 
onset of illness.  
6 Male 61  Oct 2013 
• A farm Owner 
• Significant contact with the animals, including camels  
No reported Death 
7 Male 23  Oct 2013 
• Close contact for case # 6 (epidemiological investigation). 
•  Worker in the animal barn of Case # 6    
Mild Symptoms 
8 Male 48  Oct.2013 Frequent visits to animal barns.  No reported Death 
9 Male 61  Nov.2013 Exposure to farms of livestock. No reported Death 
10 Male 71  Oct.2014 
• Symptoms developed during his road traveling from Qatar to the 
Al-Hasa, Sudia Arabia 
• Camel barn owner 
• Consumed raw camel milk.  
No reported Death 
11 Male 43  Oct.2010 Frequent camel barn visits within 14 days prior the onset of illnesses. No reported Death 
12 Male 55 Non-Qatari Jan.2015 Frequent contact with camels and goats.  No reported Death 
13 Male 69  March.2015 
• Frequent contact with camels  
• Regular raw camel milk consumption 
No reported Death 
14 Male 29 Non-Qatari May.2015 
• Frequent camels contact  
• No raw camel milk consumption. 
No reported Death 
15 Male 73  May 2015 
• No direct contact with camels 
• Family owns a camel barn with Family camel contact history and 
raw camel milk consumption. 
No reported Death 
16 Male 66 Qatari Feb.2016 
• Symptoms developed in Saudi Arabia,  
• A camel barn owner in Saudi Arabia with frequent visit.  
• Frequent camels contact  
• Raw Camel milk consumption  
Died around 17 days 
following onset of 
symptoms. 
17 Male 40 Non -Qatari May. 2016  Frequent occupational exposure to dromedaries. No reported Death 
18 Male 23 Non -Qatari June 2016 
• Frequent camels contact  
• Camel raw milk consumption.  
• History of travel to Saudi Arabia on 28 May. 
No reported Death 
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19 Male 62 
 
 
March 2017 
• No travel history for last seven months  
• No camel or patient contact  
No reported Death 
20 Male 25  April. 2017 • Frequent contact with dromedary camels  No reported Death 
Data extracted from WHO Middle East Respiratory Syndrome, Emergencies preparedness, response- Qatar. Any blank cell indicates unclear or unavailable data 
from the source.  
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Virology 
MERS-CoV is an enveloped single-stranded RNA (30 119 nucleotides) virus that 
belongs to lineage C of the β-coronavirus genus within the Coronavirinae (Figure 1) 
subfamily (68, 69). MERS-CoV is more relevant -with 90% sequence homology- to bat 
coronavirus HKU4 and HKU5 (lineage 2C bat coronaviruses) than it is to SARS-CoV 
(lineage 2B) (69-71). Additionally, MERS-CoV sequence comparisons demonstrated high 
homology (94%) with coronavirus of Pipistrellus bats (71, 72) . 
The genome of MERS-CoV encodes four essential structural proteins: envelope 
(E), membrane(M), nucleocapsid (N) and spike (S) (Figure 3) along with other accessory 
proteins with unidentified origins and roles. (16, 73). 
MERS-CoV, as other coronavirus, gains entry to the host cell through its S protein, 
a large surface transmembrane glycoprotein that exists as a trimer on the viral virion surface 
(74-79). The process of MERS-CoV entry to the host cell is mediated upon binding of the 
S glycoprotein, through its receptor binding domain (RBD), to the dipeptidyl peptidase 4 
human receptors (77-79).  The MERS-CoV S protein is cleaved during the infection 
process into 2 subunits (Figure 3): S1 (receptor-binding) and S2 (membrane-fusion) (75, 
80). 
Both the N and S proteins constitute major components for the immunogenicity of 
coronaviruses and are formed in huge amount during infection. However, the protective 
immunity  to coronavirus is mainly determinate by the S protein (81). In a study of SARS-
CoV vaccine efficiency, it was indicated that the specific immune responses to the N 
protein may provide limited protection particularly for challenges of low doses (82). 
Moreover, various studies showed that neutralization of coronavirus isolates is mediated 
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by antibodies to the S protein whereas no neutralization observed by antibody specific to 
the N protein (82-84).  
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Figure 3. Schematic structures of A: Middle East Respiratory Syndrome Coronavirus (MERS-
CoV) and B: MERS-CoV spike protein.  (+) ssRNA: positive, single-stranded RNA. a.a: amino 
acid, CP: cytoplasmic tail, TM: transmembrane domain, HR1 and HR2: heptad repeats 1 and 2, 
FP: fusion peptide, RBM: receptor-binding motif within receptor-binding domain (RBD), NTD: 
N-terminal domain, SP: signal peptide. Adapted from Zhang N et al. 2015 (85, 86). 
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  Antigenic & Serologic Characterization  
Serologic and antigenic studies across coronaviruses indicate strain specificity of 
the S protein. Coronaviruses within or across subgroups demonstrated very low-level 
cross-reactivity for the S protein and limited if any preservation of cross-neutralizing 
epitopes. Whereas coronaviruses within same subgroup share cross-reactive epitopes for 
the N protein (83, 87). Consistently, Agnihothram et al. study revealed no cross-reactivity 
between N and S proteins of SARS-CoV (β, 2b) and human MERS-CoV (β, 2c) isolates 
(83). Only high concentrations of mouse antisera to SARS-CoV showed low levels of 
cross-neutralization of MERS-CoV human isolate (Table 3A). Additionally, human 
antisera collected from a patient infected with MERS-CoV did not react with SARS-CoV 
S antigen apart from sera collected in specific one day (Table 3B)  (83). The human antisera 
of a MERS-CoV infected patient only cross-reacted with N protein of the bat coronavirus 
(BtCoV) HKU 5.5 (β, 2c) with limited if any cross-detection was reported outside the 
subgroup, apart from transient very low cross-binding of BtCoV 279 N (β, 2b) (Table 3B).  
Furthermore, their results showed that MERS-CoV human isolate and SARS-CoV reacted- 
in Enzyme-Linked Immunosorbent Assay (ELISA) - only with mouse antisera to the N but 
not the S protein of other coronaviruses of the same subgroup for each (Table 3A). The 
cross-reactive epitope(s) of the S protein among betacoronaviruses was referred -based on 
bioinformatics- to the S2 domain, which is more highly preserved among coronaviruses 
than the S1 domain (88, 89). 
Interestingly, earlier study reported significant immunofluorescent MERS-CoV antibody 
titers in 60.7% (17/28) of SARS-CoV infected patients with 25% (7/28) having low titers 
of MERS-CoV neutralizing antibodies (88). They suggested that “the Virulence of 
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SARS-CoV over other betacoronaviruses may boost cross-reactive neutralizing 
antibodies against other betacoronaviruses” (88). Agnihothram et al. reported that SARS-
CoV infected cell lysates of ELISA assay reacted with mouse anti-N -but not S- sera to 
betacoronaviruses viruses (BtCoV HKU 279 and HKU 3) within the same subgroup (2b) 
and did not react with mouse anti-N sera to coronaviruses viruses (BtCoV HKU 4.2 and 
HKU 5.5) of other group or/and subgroups (83). Consistently, HCoV-OC43 (β, 2a) 
infected cell lysates of ELISA assay did not reacted with mouse anti-N sera to SARS-
CoV (β, 2b) (83). Furthermore, human anti- SARS-CoV serum recognized the N protein 
of betacoronaviruses infected cell lysates of ELISA assay (BtCoV HKU 279 and HKU 3) 
within the same subgroup (2b) but did not react with N proteins from other 
subgroups (BtCoV HKU 4.2 and HKU 5.5) or with the S protein of betacoronaviruses 
(BtCoV HKU 3) within the same subgroup (2b) (83). Similarly, earlier established 
capture ELISA for detection of SARS-CoV N antigen showed that neither rabbit 
polyclonal nor mice specific monoclonal antibodies to the SARS-CoV N protein cross 
reacted with HCoV-OC43 (β, 2a) or HCoV-229E (α, 1b) (90). However, other 
investigators reported antigenic cross reactivity between SARS-CoV (β, 2b) N protein 
and HCoV-OC43 (β, 2a) and 229E (α, 1b) antibodies using recombinant SARS-CoV N 
protein-based ELISA (91).  
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Table 3. 
A, Summary of Agnihothram et al. 2013 findings for cross reactivity of MERS-Cov Antigens and anti-mice sera of other coronaviruses. B, 
Summary of Agnihothram et al. 2013 findings for cross reactivity of anti MERS-Cov antibodies and Venezuelan equine encephalitis virus 
replicons(VR) expressed proteins of other coronaviruses.  
 
A  Mice anti-N Sera of Mice anti-S Sera of 
  
BtCoV 
(β, 2c) 
 
HCoV 
(β, 2b) 
 
 
BtCoV 
(β, 2b) 
 
BtCoV 
(β, 2c) 
HCoV 
(β, 2b) 
BtCoV 
(β, 2b) 
BtCoV 
(α, 1b) 
  
HKU 
4.2 
HKU 
5.5 
SARS 
HKU 
3 
279 HKU 4.2 HKU 5.5 SARS 
HKU 
3 
279 
HKU 
2 
1A 
M
ER
S-
C
oV
 (
β
, 2
c)
 A
n
ti
g
èn
es
 
N 
Protein 
(VRP) 
 
Cross reaction 
(Western Blot, 
ELISA and IFA 
No cross reaction  
(Western Blot) 
 
 S 
Protein 
(VRP) 
 
No cross 
reaction 
(Western 
Blot) 
Cross 
reaction 
(Western 
Blot) 
No cross reaction  
(Western Blot) 
Little if any 
Cross 
reaction 
(Western 
Blot) 
Patient 
Isolates 
Cross Reaction 
(ELISA) 
 
No Cross Reaction 
(ELISA) 
 
No cross 
reaction 
(ELISA) 
& 
No cross 
neutraliza
tion 
(PRNT50) 
No cross 
neutralizati
on 
(PRNT50) 
Low level 
cross 
neutralization 
(PRNT50) with 
high 
concentration 
of sera. 
No cross neutralization 
(PRNT50) 
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BtCoV: bat coronaviruses. HCoV: human coronaviruses, α & β:   phylogenetic groups; 1b, 2b and 2c.: subgroup. 
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Cross reaction 
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No cross 
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Transient 
minimal cross 
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(ELISA) 
No cross neutralization 
(PRNT50) 
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Viral Reservoir & Transmission Mode  
The origin of the MERS virus is not yet fully understood. However, several MERS-
CoV viral genomes analysis suggests a zoonotic reservoir; originated in bats (72, 92-94) 
and transmitted to camels’ long time ago (5, 6, 95). Bats constitute a diverse and abundant 
group of mammalian species with extensive geographic distribution and capability of fly 
(96). Multiple novel coronaviruses have been identified in a various bat species throughout 
America, Africa, Europe and Asia (97). Various screening studies among multiple bat 
species within different geographical areas i.e. Ghana, European, South Africa and Saudi 
Arabia identified bat derived coronaviruses that genetically are very closely related to 
MERS-CoV (Table 4) (72, 98, 99). Furthermore, an experimental study reported that 
MERS-CoV replicated in Jamaican fruit bat (Artibeus jamaicensis) without clinical signs 
of bats illness (100). Collectively, it indicates that MERS-CoV is most likely originated in 
bats which proposed to serve as an optimal reservoir (101). Yet, no direct contact between 
bats and humans were reported particularly in Saudi Arabia (101) whereas multiple MERS 
cases reported contact history with dromedary camels (9, 63). Additionally, genomic 
sequences showed high similarities (>99 %) for MERS-CoV detected in camels and human 
isolates (7, 9, 102, 103).  Serologic surveillances further confirmed that most of the African 
and Middle East camels were seropositive for MERS-CoV while other species as goats, 
cows and sheep were negative suggesting the potential introduction of MERS-CoV to the 
humans through dromedary camels (4, 5, 9, 95, 104-109). Interestingly, neutralization 
antibodies of MERS-CoV detected in camels from Sudan and Somalia- main camel 
exporting countries- could be traced back to more than 30 years (since1983) (6). 
The transmission mode is not yet clarified, but is proposed that MERS-CoV could 
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transmit to human during direct contact with camel (8, 110, 111) through saliva(112) or 
through consumption of milk (113, 114) or contaminated meat (115). However, the 
potential of another intermediate host for MERS-CoV transmission to humans may exist 
(112).  
Despite the potential introduction of MERS-CoV to the human beings through 
infected Dromedary Camels and perhaps other intermediate host yet to be recognized, the 
vast majority of MERS-CoV infections has evolved via viral transmission from infected to 
uninfected individuals in prolonged and close contact through poor infection control 
settings in health care facilities (20). These reported cases or clusters a cross healthcare 
facilities or household setting, suggest the potential of secondary infection (human-to-
human transmission) which may be through air or fomites droplets  (116). However, the 
number of infected individuals through case contact seems to be limited indicating that 
human-to-human transmission is not sustained (20, 116). 
  
 
   
23 
Table 4.   
 Summary of beta-coronaviruses and MERS-CoV isolated from bats. Adapted from Mohd et al.2016 (101) 
Bat Species Source Year No. screened Type of sample Virus  % of positive Bats 
Nycteris cf. gambiensis Ghana 2009-2011 185 Fecal 
2c betacoronaviruses, 
(closely related to 
 MERS-CoV) 
24.9 % 
Coleura afra, Hipposiderosabae, H. cf. gigas, 
H. fuliginosus, H. jonesi, H. cf. ruber, 
Rhinolophus alcyone, R. landeri, Taphozous 
perforates 
Ghana 2009-2011 4573 Fecal 
2c betacoronaviruses, 
(closely related to 
 MERS-CoV)) 
0% 
Pipistrellus kuhlii, P. nathusii, P. pipistrellus, 
P. pygmaeus 
Europe: 
Germany, 
Netherland, 
Romania, 
Ukraine 
2009-2012 272 Fecal 
2c betacoronaviruses, 
(closely related to 
MERS-CoV) 
14.70% 
Chaerephonpumilus, Mops condylurus, 
Tadaridaaegyptiaca, H. caffer, Miniopterus 
natalensis, Nycteristhebaica, R. clivosus, R. 
darlingi, Neoromicia capensis, N. nana, N. cf. 
zuluensis, Scotophilus viridis, Rousettus 
aegyptiacus 
South Africa 
2011–
2012 
62 Fecal pellets 
bat related-
alphacoronaviruses 
betacoronavirus 
6.4 %                                                                                                                              
1.6 % 
Rhinopomahardwickii, R. microphyllum, 
Taphozous perforatus, P. kuhlii, Eptesicus 
bottae, Eidolon helvum, and Rosettus 
aegyptiacus 
Saudi Arabia 2012 96 
Throat swab, serum, urine, 
rectal swab or fecal pellets 
MERS-CoV 1 % 
R. hardwickii, T. perforates, P. kuhlii Saudi Arabia 2013 14 Throat swabs, roost feces MERS-CoV 0 % 
T. perforatus 
Egypt 2013-2015 
82 
Serum/rectal (alive) MERS-CoV 0 % P. deserti 31 
R. aegyptiacus 257 
R. hipposideros 
Lebanon 2013-2015 
4 
Homogenized lung and 
liver material (if died or 
euthanized upon capture) 
MERS-CoV 0% 
Miniopterus schribersii 6 
R. ferrumequinm 3 
R. aegyptiacus 438 
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Laboratory Diagnosis & Detection  
Following first isolation of MERS-CoV, several laboratory tests have been 
published (117-120). These include several in-house real times reverse transcriptase 
polymerase chain reaction (RT-rtPCR) assays as well as virus culture (1, 117, 118). But, 
cell culture is a slow, insensitive and specialized method (121) while specific MERS-CoV 
RNA sequence real‐time reverse transcription polymerase chain reactions (rRT‐PCR) are 
the preferred method for MERS-CoV detection (122). Three rRT‐PCR assays for 
detection of MERS-CoV have been released (117, 118, 122). These assays target one of 
the following: upstream of the E protein gene (upE) (118) , open reading frame 1b (ORF 
1b) (118) or ORF 1a (117). The upE assay is recommended for screening (Figure 4) as a 
highly sensitive assay (118). The ORF 1a assay provide an appropriate complement of 
equal sensitivity to the upE assay and thus recommended as confirmatory test (Figure 4) 
(117), whereas the ORF 1b assay showed slightly lower sensitivity than the upE assay 
(117). Another rRT-PCR assay has developed by the United States Centers for Disease 
Control and Prevention (US CDC). It targets the gene of MERS-CoV N protein and can 
provide a complement screening and confirmation test to the upE and ORF 1a assays (123). 
Earlier as of june.2015, the World Health Organization (WHO) reported that “To date, 
these rRT-PCR assays have shown no cross-reactivity with other respiratory viruses 
including human coronaviruses” (122). Later, Kim et al. reported no cross-reactivity with 
other respiratory viruses among six different commercial rRT-PCR MERS-CoV RNA 
detection kits: Ultrafast kits (Nanobiosys, Korea, LightMix (Roche Molecular Diagnostics, 
Switzerland), AccuPower (Bioneer, Korea), Anyplex (Seegene, Korea), DiaPlexQ 
(SolGent, Korea) and PowerChek (Kogene Biotech, Korea) (124). 
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The routine Detection of MERS-CoV infection is based on the above mentioned  
rRT-PCR assays followed by nucleic acid sequencing (Figure 4) for confirmation if needed 
(122). However, MERS-CoV seroconversion in samples ideally withdrawn at least 2 weeks 
apart, thorough at least one screening test (i.e. ELISA, indirect fluorescent antibody (IFA) 
followed with confirmation by a neutralization test meets the current WHO case 
definition.(122). In another view, The US CDC limited the use of MERS serology tests for 
investigational or surveillance settings and not for diagnosis (125). They established two-
phase serological approach to detect anti-MERS antibodies through one screening test i.e. 
ELISA followed by a full virus IFA test for confirmation. If the presence of anti-MERS 
antibodies is not confirmed (indeterminate or negative) by IFA, a microneutralization assay 
has to be conducted considering it as highly specific confirmatory test (125).  
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Figure 4. Algorithm for MERS-CoV diagnosis by reverse transcriptase real time 
polymerase chain reaction (rRT-PCR). ORF: open reading frame, N: nucleoprotein gene, 
RdRp: RNA-dependent RNA polymerase genes. Adapted from WHO, June 2015 (122).   
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Comparison of MERS-CoV Serologic Assays  
Validated serologic assays play a vital role for MERS seroepidemiology and 
detection to estimate risk factors and prevalence (111, 122). A wide variety of MERS-CoV 
serologic assays has been developed including enzyme-linked immunosorbent assay 
(ELISA), immune-fluorescence assay (IFA), micro-neutralization (MN), plaque reduction 
neutralization (PRNT) and MERS-spike pseudoparticle neutralization tests (ppNT)  (106, 
126).  
ELISA assays are based on solid surfaces coated with inactivated MERS-CoV or 
recombinant viral structural antigens: nucleoprotein (NP), full-length spike protein S, S1, 
receptor-binding domain (RBD), N-terminal domain (NTD, amino acids 18–353 of S 
protein) (86).  Whereas, IFA are relied on cell culture infected with MERS-CoV or 
expressing recombinant viral structural antigens (i.e. S or N protein) for the detection of 
anti-MERS-CoV antibodies in human or animal samples (1, 4, 5, 117, 127). Several 
commercial ELISA kits, and IFA slides/ kits have been released by various companies i.e., 
mybiosource (USA), komabiotech (Korea), Alpha Diagnostic International (USA). 
Euroimmune (Germany) commercial recombinant S1-based ELISA and whole virus IFA 
kits were applied in various studies (12, 126, 128-132).  
Neutralization assays confirm the reactivity to MERS-CoV by the detection of anti- 
antibodies capable to neutralize MERS-CoV (126, 133). The PRNT assays determine the 
neutralizing antibody titers at the highest serum dilutions that resulted in ≥ 50% (PRNT50) 
or ≥ 90% (PRNT90) reduction in the number of viral plaques within stained culture plates 
of cell line incubated earlier with mixture of serum dilutions and viral plaque-forming units 
(126). Quite like PRNT, the MN assays measure neutralizing antibody titers at the highest 
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serum dilution that suppressed virus cytopathic effect in microtiter plate containing cell 
line following infection with a mixture of serum dilutions and infectious viral dose (106, 
126).  
The development of ppNT offers a safe alternative for the live MERS-CoV 
(biosafety level 3) neutralization assay (133). The ppNT determine the highest serum 
dilution showing a 90% reduction for the activity of the luciferase enzyme following lysis 
of cell line incubated earlier with mixture of serum dilutions and pseudotyped MERS-CoV, 
a recombinant lentivirus encoding luciferase and MERS-CoV S protein and has power of 
one-cycle infection but can’t undergo multiple replication cycles. (106, 133, 134).  
Data comparing serological assays for detecting anti-MERS-CoV antibody in 
humans are limited (86, 126). Recently, Wang et al. compare the detection of MERS-CoV 
antibodies in a series of sera from a MERS-CoV confirmed patient using  ELISA based on 
inactivated MERS-CoV or alternative recombinant antigens (NTD, RBD, S, S1 and NP) 
and ppNT assays (86). For S1- based ELISA, they purchased the commercial Anti-S1 
MERS-CoV IgG ELISA Kit from EUROIMMUNE (Luebeck, Germany) whereas for other 
recombinant antigens they used inhouse ELISA assays (86). The S1, S and RBD ELISAs 
reported more sensitivity than the whole virus ELISA for detecting anti-MERs-CoV 
antibodies with highest sensitivity reported for MERS-CoV S-based ELISA (86).  Further, 
the study illustrated a strong correlation of S ELISA with the ppNT (0.9319 Pearson's 
correlation coefficients, Figure 5).  Though, S1, RBD, NTD and inactivated MERS-CoV 
ELISAs were also correlated significantly (P<0.001) with the ppNT (0.71– 0.8439 
Pearson's correlation coefficients, Figure 5) (86). Excellent correlations were reported for 
the MERS-CoV ELISA with the S1, NP and RBD based ELISAs (0.9292–0.9488 Pearson's 
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correlation coefficients, Figure 5). Whereas, NTD and S ELISAs showed lower correlation 
(Figure 5) with the MERS-CoV ELISA (0.8122–0.8420) (86). Subsequently, S1 ELISA 
showed excellent correlations (Figure 5) with the RBD and the S ELISAs (0.9234–0.9701). 
However, the NTD ELISA was less strongly correlated (Figure 5)  with the S1 ELISA 
(0.8807) (86). 
Earlier to Wang et al. study, Park et al. conducted a serologic assays comparison 
on 95 sera from 17 confirmed MERS-CoV patients using S1-ELISA from 
EUROIMMUNE, MN, PRNT50, PRNT90, and ppNT (126). MERS neutralization assays 
(PRNT50, PRNT90, MN, & ppNT) showed excellent correlation (≥ 0.94) (126). The PRNT50 
was the most sensitive tests and could be the only one that can detect anti-MERS antibodies 
at early stage of the infection and in cases with weak antibody responses (126).However, 
the ppNT test had good correlation with MN and PRNT90 assay and unlike other 
neutralization assays it does not include handling live virus, therefor no biosafety level 3 
containment required (126). The specificity of spike ppNT was previously confirmed when 
sera from healthy humans from Saudi Arabia, Hong Kong and Egypt tested negative with 
ppNT (126). In the other hand, MERS S1 ELISA gave lower, but acceptable, correlations 
(0.86–0.87) with the different neutralization tests, regarding the seroconversion time in 
MERS patients. This lower correlation is not surprising because S1 ELISA assay is 
detecting IgG only and is not an active neutralizing test (126).  
Moreover, Park et.al had demonstrated in various studies that the virus clade is not 
affecting antibody titers. In other word, “Genetically diverse MERS-CoV are antigenically 
homogenous” (126).   
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Figure 5. Correlations (Pearson's correlation coefficients) among A. MERS-CoV ELISAs (IgG) and the 
ppNT assay, B. the Euroimmune anti-S1 MERS-CoV Kit and the inactivated MERS-CoV ELISA (IgG), C. 
the inactivated MERS-CoV based and recombinant protein based (S, NTD, RBD and NP) ELISAs (IgG), 
D. the Euroimmune anti-S1 MERS-CoV Kit with other recombinant MERS-CoV protein-based IgG 
ELISAs (S, NTD and RBD). *P<0.05; **P<0.01; ***P<0.001. ELISA: Enzyme-linked immunosorbent 
assay, MERS-CoV: Middle East respiratory syndrome coronavirus, NP: nucleoprotein, NTD: N-terminal 
domain, RBD: receptor-binding domain, S: recombinant MERS-CoV full-length spike protein. S1: 
recombinant MERS-CoV spike protein subunit 1. Summarized from Wang et al. 2016 (86).
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Human Antibody Response 
Interpretation of sero-epidemiologic data in defining prevalence and risk factors for 
MERS-CoV infection is based on the understanding of the kinetic serologic response to 
the infection (130). However, limited studies addressed this issue. These studies showed 
that the severity of the infection is reduced by early MERS-CoV antibody response (130). 
It was demonstrated that MERS antibodies developed during the second to the third week 
after the onset of illnesses, resembling that of SARS-CoV (132), with a strong anti-S1 IgG 
-detected by ELISA-  and neutralizing antibody responses at the third week of onset in 
most of studied patients (86, 130). Nevertheless, few patients failed to develop a strong 
response. Thus, serologic assay may fail in detecting infections in such subjects (130). 
Corman et al. showed that there was no earlier detection of IgM than IgG using 
anti-MERS-CoV Indirect immunofluorescent test (IIFT-IgM) and recombinant enzyme-
linked immunosorbent assay (ELISA; Anti-MERS-CoV ELISA IgG, Euroimmun, 
Germany) (132). They suggested that this finding, particularly when suspecting a cross-
reacting IgM for more prevalent human coronaviruses, restricts the diagnostic utility of 
IgM, using same methodology, to cases when an overcome and recent MERS-CoV 
infection must be approved (132). Interestingly, Wang et al. recent study showed that IgG 
antibodies to specific MRS-CoV antigens were detectable earlier or in parallel with the 
IgM (86). They referred this either to the sensitivities variations of the immunoglobulin 
class-specific ELISAs or later development of IgM than IgG antibodies (86). 
 Seroconversion determined by Wang et al. study using S based ELISAs were 
detected as early as neutralizing antibodies with the ppNT assay (86). First, anti-S IgG 
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antibodies were detected by ELISA (IgG on day 5 following admission). Next, anti-S IgM 
antibodies (day 6) and followed by anti-S1 and anti- RBD antibodies, then antibodies 
against inactivated MERS-CoV and NTD. Finally, anti- NP antibodies occurred last (days 
12–13) (Figure 6) (86). 
Viral Shedding 
Studies of the Virus shedding showed that the concentrations of RNA found in 
lower respiratory tract samples are at least two orders of magnitude higher than the RNA 
concentration in the upper tract samples, stool or serum (132). The Viral RNA loads 
gradually decline in the lower respiratory tract secretions (132). However, shedding usually 
persist for 3 weeks or more (132). The severity of disease is proportional to the viral RNA 
load detected in higher respiratory tract (132). 
In the other hand, asymptomatic subjects express prolonged viral shedding of 
nearly 6 weeks detected by polymerase chain reaction (PCR) (135). This finding raise a 
concern for the potential of viral transmission from asymptomatic subjects (136). However, 
it is not clear how a detected RNA by PCR is refer to an infectious virus (136, 137). 
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Figure 6. Timeline (days after hospitalization) of detection of IgG, IgM and neutralization antibodies in the 
first MERS-CoV case in China (May.2015) determined by recombinant antigens (S, S1, RBD, NTD and 
NP) based enzyme-linked immunosorbent assay (ELISA) and the pseudovirus particle neutralization test 
(ppNT). The patient was hospitalized 8 days after the onset of illness. S: full-length spike protein, Nab: 
neutralizing antibody, S1: Subunit 1 of spike protein, RBD: receptor-binding domain, MERS-CoV: 
inactivated Middle East respiratory syndrome coronavirus, NTD: N-terminal domain, NP: nucleoprotein. 
Summarized from Wang et al. 2016 (86) 
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 CHAPTER 3: MATERIAL AND METHODS 
Study Design, Sample Collection and Ethical Compliance 
This cross sectional MERS-CoV IgG sero-surveillance study was conducted among 
two groups of Qatar population: the low risk group or the blood donors group and high-
risk group or the case contacts. Anonymized sampling for blood donors was accomplished 
through existing arrangement between Biomedical Research Center (BRC) at Qatar 
University and Blood Donation Center at Hamad Medical Corporation. For case contacts, 
samples were sent to BRC through the Ministry of health of Qatar. This study was approved 
by Qatar University-Institutional Review Board (QU-I 622-E/16 RB). 
Sample Size 
As per review literature there is no precise information and estimates available on 
the primary seroprevalence of MERS-CoV among healthy individuals in Qatar. To the best 
of our understanding this is the first study of its kind to be conducted in Qatar and hence 
due to non- availability of precise information related to primary outcome, no prospective 
statistical power had been planned for specimen collection.   
In total, this study included 4858 subjects: 4719 blood donors collected over five 
year periods (2012- 2016), 135 baseline case contacts collected from individual that were 
in close contact to three positive confirmed cases (case no. 14, 16, and 18, Table 2) and 
four confirmed MERS-CoV patients (case no. 13,14, 16 and 17, Table 2). The demographic 
profiles for all subject included in the study are shown in Table 5,6 & 7. 
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Table 5 
 
 
Characteristic profile of study population/ blood donors 
 
 
 
 
  
  
 2012 2013 2014 2015 2016 Total 
 
Qatari 
 
28 6 111 660 123 
 
928 
 
Male 16 5 107 656 122 906 
 
Female 
12 1 4 4 1 22 
Non-Qatari 92 22 500 2723 454 
 
3791 
 
Male 77 22 489 2694 454 3736 
 
Female 
 
15 0 11 29 0 55 
 
Age Range  
(Mean) 
 
 
27-65  
(37) 
 
 
21-56  
(38) 
 
 
18-64  
(36) 
 
 
17-88 
 (37) 
 
 
19-66  
(37) 
 
 
19-88  
(37) 
 
 
Total 
 
 
120 
 
 
28 
 
 
611 
 
 
3383 
 
 
577 
 
 
4719 
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Table 6 
 
 
Characteristic profile of study population/ case contacts 
 
 
  
 
 
Case Index 
 
 
 
May. 2015 
(No.14) 
Feb. 2016 
(No.16) 
Jun. 2016 
(No.18) 
Total 
 
Qatari 
 
8 6 0 
 
14 
Male 6 5 0 11 
 
Female 
2 1 0 
3 
 
Non-Qatari 
 
92 4 25 
 
121 
Male 64 4 25 93 
 
Female 
 
 
28 
 
 
0 
 
 
0 
 
 
28 
 
Age Range (Mean) 20-49 (35) 14-48 (32) 20-37 (26) 
 
14-49 (31) 
 
 
Family contact 
 
 
31 
 
 
6 
 
 
-- 
 
 
37 
Health Care Worker 
 
69 
 
4 
 
-- 
 
75 
 
Farm Camel Contact 
 
-- 
 
-- 
 
25 
 
25 
 
Total 100 10 25 135 
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Table 7 
 
 
Characteristic profile of study population/ MERS-CoV confirmed patients 
 
  
 
 
Case Index 
 
 
 
March.2015 
(No.13’) 
May. 2015 
(No.14’) 
Feb. 2016 
(No.16’) 
May. 2016 
(No.17’) 
Total 
Qatari Male 1 -- 1 -- 2 
Non-Qatari Male -- 1 -- 1 2 
Total 1 1 1 1 4 
Age 69 29 66 40 29-69 
Exposure 
Frequent camels 
contact 
Frequent camels 
contact 
A camel barn owner 
in Saudi Arabia 
 
occupational 
exposure to 
Camels 
 
Total 1 1 1 1 4 
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Serological Testing 
MERS-CoV Serologic Assays 
Recombinant S Protein Enzyme Linked Immunosorbent Assay IgG (rELISA) 
Initially all blood samples were screened for the presence of anti-MERS IgG using 
ELISA. The ELISA plate is coated with purified S1 MERS-CoV antigens, developed by 
the invitro diagnostic company “Euroimmune” and provided in a ready-to use kit format 
(cat no. EI 2604-9601 G). The test has been performed following manufacture instructions. 
Later, endpoint rELISA titration has been performed for all borderline and reactive anti-
MERS-CoV IgG samples. 
Full Virus Indirect Immunofluorescence Test IgG (IIFT IgG) 
To confirm the presence of anti-MERS-CoV IgG, we tested borderline and reactive 
anti-MERS-CoV IgG rELISA samples with anti-MERS-CoV IgG IIFT. The test has been 
performed using Vero cells infected with MERS-CoV; spotted and fixed on glass slide 
(117) (Figure 7) and provided within a reagent kit set (cat no. FI 2604-1005 G / M) by an 
invitro diagnostic company (Euroimmune, Germany). Initially samples were diluted with 
sample buffer at titers of 1:100 (Figure 8). Next, 30 μl of diluted samples along with ready 
to use negative and positive controls were transferred into reaction fields of the reagent 
tray (Figure 9). Subsequently, BIOCHIP slides were fixed into the corresponding recesses 
of the reagent tray. Following 30-minutes incubation at room temperature, the BIOCHIP 
slides were rinsed with a flush of washer solution (phosphate buffer saline with tween 20: 
PBS Tween) and then immediately immersed in a beaker containing the washer solution 
for 5 minutes. Thereafter, BIOCHIP slides were removed from PBS Tween, blotted at the 
back with a paper towel and fixed on the recesses of the reagent tray containing 25 μl of 
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fluorescein labelled anti-human globulin at the reaction fields. Following 30 minutes 
incubation at room temperature away from direct light, the BIOCHIP slides were rinsed 
and washed in the same manner described above. Finally, cover glasses containing 10 μl / 
reaction field of embedding medium were applied on the washed BIOCHIP slides.   Slides 
were evaluated for fluorescence reaction under a fluorescent microscope. MERS-CoV 
antibodies cause fine to coarse granular fluorescence pattern mainly in the cytoplasmic area 
of the infected cells (Figure 10).  
Full Virus Indirect Immunofluorescence Test IgM (IIFT IgM) 
Borderline and reactive anti-MERS-CoV IgG rELISA samples have been screened 
for the presence of anti-MERS-CoV IgM using anti-MERS-CoV IgM IIFT. The test has 
been performed using reagent kit set (cat no. FI 2604-1005 G / M) from Euroimmune, 
Germany in the same manner describe above for IIFT IgG (Figure 9). The only difference 
is that apart from sample dilution, here samples was diluted (Figure 8) by EUROSORB 
reagent (goat anti-human IgG antibody) rather than sample buffer to deplete IgG antibodies 
by immunoadsorption.  
Along with the borderline and reactive anti-MERS-CoV IgG rELISA samples, we tested 
13 randomly selected (12 blood donors and 1 case contact) negative samples with anti-
MERS-CoV IgG/ M IIFT.  
Recombinant S Protein Indirect Immunofluorescence Assay IgG (rIIFA) 
To reduce the possibility of cross reactivity of human sera with the full MERS virus 
antigen presented by Vero cells in the virus IIFT IgG test kit, we screened borderline and 
reactive anti-MERS-CoV IgG rELISA samples along with the 13 selected negative ones 
using recombinant S protein IIFA IgG kit. This test was performed in institute for Virology, 
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University Medical Center Bonn, Germany using cells verso cells expressing the MERS S 
protein. Vero cells were transfected as follow: First, 2.5 µg of plasmid DNA harboring the 
gene encoded for the S protein was added to 500 µl Opti-Pro (serum-free medium). 
Following vortex and centrifugation, 7.5 µl FuGene HD (transfection reagent Promega 
Cat# E2311) was applied and incubated for 15 minutes at room temperature. Transfected 
Vero cells were harvested and seeded (1x10^6 cells/well) into a 6-well plate with 2.5 ml 
Dulbecco's Modified Eagle Medium (DMEM) 10% Fetal Calf Serum (FCS) without 
antibiotics. Then the transfection mix were added on the cells. After one day incubation in 
a cell culture incubator at 37°C, transfected Vero cells were harvested using trypsin-
treatment and then re-suspended in 5 ml DMEM. Following centrifugation at 300 x g for 
5 min, 50 µl of cells (density: 2.5x10^5 cells/ml of DMEM 10% FCS without antibiotics) 
were applied on the spot area of multi-test cover slides in a humid chamber. After 6-hours 
incubation at 37°C in a cell culture incubator, slides were twice washed with PBS and cells 
were fixed with ice-cold 1:1 acetone/methanol for 10 min. Slides were dried at room 
temperature. Further, the same protocol described above (under IIFT-IgG) was applied for 
the detection of human anti-MERS-CoV S IgG.  
 
Pseudoparticle neutralization tests (ppNT) 
Regardless of the confirmatory results of IIFT IgG, borderline and reactive anti-
MERS-CoV IgG rELISA samples along with the 13 selected negative ones were further 
tested by ppNT. In this test, two MERS-CoV strains were used: EMC (GenBank 
JX869059) and Jordan N3 (GenBank KC776174) strains. The test was performed at in 
Virology Laboratory -NIH, USA as follow (138).  
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Pseudovirus Generation 
293T cells were cultured in 15-cm plate using DMEM containing 2 mM glutamine, 1X 
penicillin/streptomycin (D10) and 10% bovine serum albumin (BSA) in a 37 °C 5% CO2 
incubator. Cell were then transfected at 90% confluency using calcium phosphate 
transfection solution (Invitrogen) with the following plasmids: pCMVΔR8.2 (packaging 
plasmid ,17.5 μg), pHR' CMV-Luc (transducing plasmid, 17.5 μg) and CMV/R-MERS-
CoV S plasmid (1 μg). Following overnight incubation, old medium was discarded and 
replaced with a fresh D10. After 48 hours, the cell supernatants were collected and filtered 
with 45 μm filters and subsequently stored at −80 °C. 
Pseudovirus Titeration 
106 Huh7.5 cells were seeded into a 96-well white/black Isoplate (PerkinElmer, Waltham, 
MA) using same condition described above. After overnight incubation, old medium was 
removed and 50 μl of twofold serial dilutions of pseudovirus were applied to the cells for 
1 hour and additional 100 μl of fresh media was then added.  
Neutralization Assay 
Serial dilutions of human samples were mixed with 106 relative fluorescence unit (RFU) 
of two strains (EMC and Jordan N3 viral MERS-CoV). After 30 minutes of incubation at 
room temperature, mixtures were added in triplicate to Huh7.5 cells cultured in 96 wells as 
described above. Following 2 hours of incubation, plates were refilled with 100 μl/ well of 
fresh media. 72 hours later, cells were lysed using luciferase cell culture lysis (Promega, 
USA) and 50 μl of luciferase substrate (Promega, USA) was applied to each well. 
Microbeta luminescence counter (PerkinElmer) was used to measure luciferase activity in 
relative luciferase unit and neutralizing activity was reported as the dilution of each sample 
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required to inhibit 50%, 80% and 90 % (IC50, IC 80 and IC 90) of infection. 
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Figure 7.  Anti-MERS-CoV IIFT BIOCHIP slide. Each slide contains 5 X 2 Biochips: one 
chip coated with MERS-CoV infected cells and the other coated with non-infected cells.  
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Figure 8. Samples dilution scheme for indirect immunofluorescent test. Sample 
dilution for semi-quantitative evaluation of antibodies of class IgG: apply 100 µl of 
sample buffer to each tube and mix with 11.1 µl of the next highest concentration then 
vortex for 2 seconds. Incubate samples from 1:100 dilution. 
 
Sample dilution for semi-quantitative evaluation of class IgM: dilute the patient samples 
1:10 with EUROSORB (i.e.: 11.1 µl sample to 100 µl EUROSORB). Incubate the 
mixture for 15 minutes at room temperature or centrifuge the mixture (5 minutes, 2000 
rpm, room temperature). Incubate samples from 1:10 dilution. Exported from 
Euroimmune. 
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Figure 9. Indirect immunofluorescent test layout. Exported from Euroimmune. 
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Figure 10. Anti-MERS IgG indirect immunofluorescence control results view 
1. Right chip for Reactive control. (Antibody against Mitochondria (AMA, IgG). 
2. Right chip for Negative control. 
 
Right chip coated with MERS Coronavirus infected cells and the left Chip coated with non-infected cells. 
Anti-MERS antibodies cause fluorescence of fine to coarse granular structure coating viral material mainly 
in the cytoplasm of the infected cells. 
  
5 A 
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Known Pathogenic Human Coronaviruses Serologic Assays  
To access cross reactivity among both rELISA and IFA for anti-MERS-CoV 
antibody with other family member of pathogenic human coronaviruses, we initially tested 
borderline and reactive samples for the presence of the of IgG (and IgM for specific 
samples) antibody of SARS-CoV and HCoV-229E using the Euroimmune Full Virus 
IIFT (as described above under MERS-coV Full Virus IIFT IgG).  
Further, we tested borderline and reactive anti-MERS-CoV IgG/M samples along 
with the 13 randomly selected negative samples for the presence of IgG antibodies to the 
human coronavirus HKU-1 using in-house recombinant S protein anti-IgG ELISA. 
Initially, a flat ELISA plate was coated (0.1 ml/ well) with HKU1 spike glycoprotein 
(Catalog # 40021-V08H, Sino Biological Inc.) at 2 µg/ml in PBS at 4 °C overnight. 
Following incubation, the coating buffer has been discarded and residue has been absorbed 
by tapping plate on paper towel. Next, the plate was blocked by incubating with 200-300 
µl blocking buffer/ well (PBS with 5% skim milk) for 1-2 hours at room temperature. After 
that, plate has been washed in triplicate with 300 µl/ well of washing buffer (Bio-Rad, 
Plaetlia) using THERMO Plate Washer and buffer residue was absorbed by tapping plate 
on paper towel. Further, 100 µl of blocking buffer was added as a blank at the first well 
followed by serial samples dilutions of 1:100. Following 1 hour incubation at room 
temperature at dark, plate was washed in same manner described above. Subsequently, 100 
µl / well of peroxidase labelled anti-human IgG monoclonal antibodies (Bio-Rad, Plaetlia) 
were applied and incubated for 1 hour at room temperature. After washing plate, 100 µl/ 
well of tetramethylbenzidine/hydrogen peroxide (TMB) Substrate (Bio-Rad, Plaetlia) were 
added and incubated for 5-7 minutes at room temperature (light protected). Reaction was 
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stopped by addition of 100 µl (per well) of 0.3 molar Sulphuric acid (Bio-Rad, Plaetlia).  
Plate was read at 450 nm with 650 nm reference using Epoch 2 Microplate 
Spectrophotometer, Bio Tek and Endpoint titer has been calculated as the highest dilution 
of 5 times increase in optical density in referral to background reading (blank).  
Finally, we extended our assessment and screened borderline and reactive anti-
MERS-CoV IgG/M samples along with the 13 randomly selected negative samples for the 
presence of IgG antibodies to all known pathogenic human coronaviruses (HCoV-229E, 
HCoV OC43, SARS-CoV, HCoV NL63 and HCoV HKU-1) using recombinant S 
protein IIFA in the same manner described earlier -under MERS-CoV serologic assays/ 
IIFA-. 
Statistical Analysis 
Microsoft Excel was used in our cross sectional descriptive study to manipulate 
data. Several functions were used to express data i.e. sum, mean, max., min., percent. 
Additionally, “find” feature was applied to calculate the count of study population referred 
to various demographic features. Yet, more specific statistical analysis i.e. tests correlation; 
specificity and sensitivity are further planned upon including more reactive samples i.e. 
patient samples. 
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CHAPTER 4: RESULTS 
Between 2012 and 2016, we obtained 4719 blood samples from the Blood Donor 
Center in Qatar. Blood donor participants were aged 17-88 years (mean age 37 years). 
Additionally, we obtained blood samples from 135 MERS-CoV case contacts (aged 14-49 
years; mean age 31 years) and from 4 confirmed MERS-CoV cases (aged 30-70 years; 
mean age 52). The anti-MERS CoV-IgG seroprevalence as jugged by anti-MERS-CoV 
rELISA-IgG was 0.13% (7/4719) in healthy blood donor or ratio of 1: 674, 0.74% or 1:135 
in case contacts (high risk) and 80% (4/5) or 4:5 for patients.  No one of the reactive donor 
samples was confirmed by (Table 9 A & B) ppNT, suggesting that the true ratio of anti-
MERS-Cov-IgG antibody in healthy donors is 0: ~5000.  However, one confirmed -by 
ppNT- reactive anti-MERS-CoV-IgM was detected in blood donors (Table 10 C). For the 
high-risk case contact group and the true patients (confirmed by PCR), the above-
mentioned ratios were not affected as of rELISA-IgG results were confirmed in all samples 
by ppNT assay (Table 9 B).   
 
All blood samples were initially screened for anti-MERS-CoV S IgG by rELISA 
giving borderline results (Ratio 0.8- <1.1) in 3 samples (all are blood donors) and reactive 
results (Ratio ≥ 1.1) in 12 samples (7 donors, 1 case contact and 4 samples collected from 
3 MERS-CoV confirmed patients (Table 8). Subsequent testing with full MERS-CoV IIFT 
IgG confirmed only 5 reactive rELISA results (2 blood donors and 3 patients; the reactive 
case contact was not sufficient to be tested by IIFT IgG, Table 9 A & B). However, none 
of borderline or reactive IgG blood donors were confirmed by recombinant S MERS-CoV 
IIFA or ppNT. Both recombinant S IIFA and ppNT only confirmed the presence of specific 
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anti-MERS-CoV antibodies in patients’ samples (Table 9 A & B). The reactive rELISA 
anti-MERS-CoV IgG case contact was also confirmed by ppNT; however, it was not 
sufficient for testing with immune-florescent assays (Table 9 B). In our study, one patient 
sample (May. 2016) screened negative (Ratio < 0.8)   for anti-MERS S IgG by rELISA and 
immunofluorescent assays. Unfortunately, we were not able to screen this sample by ppNT 
due to difficulties in shipment (Table 10 C).  
Further investigation for borderline and reactive anti-MERS-CoV IgG samples with IIFT 
IgM yielded only one IgM reactive (titer = 100) patient (Feb.2016) sample (Table 10 A). 
Interestingly, one donor sample (D2015/3379) which screened negative for anti-MERS-CoV IgG 
by rELISA and immunofluorescent assays (Table 10 C) showed reactive IgM (titer = 320) and was 
confirmed by ppTN. 
Subsequent assessment of reactive specificity of anti-MERS-CoV IgG rELISA and 
IIF with other human pathogenic coronaviruses (HCoV-229E, HCoV OC43, SARS-CoV, 
HCoV NL63 and HCoV HKU-1) is summarized in Table 9 A, B & C. Majority of tested 
samples including the negative control samples (total=28) showed reactive titers against 
recombinant spike proteins of HCoV-229E (100 %), OC43-CoV (96.55 %), NL63 (85.71 
%) and HKU1(89.29 %), but not with the SARS-CoV spike protein. Only two samples 
from two MERS-CoV infected patients (P/March.2015 and P/Feb.2016- second sample) 
reacted with SARS-CoV spike protein with titer of 320 and 3200, respectively (Table 10 
A, B &C).  
In our study, full virus IIFA-IgG assays for HCoV-229E and SARS-CoV showed 
slightly lower number of reactive samples than rIIFA-IgG (Table 10 A, B & C). Three 
samples of two MERS-CoV infected patients, which showed negative reaction with full 
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viral HCoV-229E IIF-IgG reacted with HCoV-229E spike protein in rIIFA (Table 10 A). 
Consistently, two samples collected from MERS-CoV infected patients reacted with 
SARS-CoV spike protein, whereas only the one with higher anti-SARS spike protein IgG 
titer reacted with full SARS-CoV IIF-IgG (Table 10 A). On the other hand, tested samples 
showed more reactive results with HKU1 IgG rELISA than with IgG rIIFA. Three samples 
of two MERS-CoV infected patients which reacted with HKU1 spike protein in rELISA 
yielded negative reaction with HKUI rIIFA (Table 10 A).  
Interestingly, one patient sample (P/ May.2015, Table 10 A) initially screened 
reactive for anti-MERS IgG (optic density (OD) = 0.412, Ratio = 1.37) with rELISA-IgG, 
later, about one year, the same frozen sample was tested for anti-MERS-IgG using same 
rELISA-IgG and yield negative result (OD < 0.2) in 4 independent runs. However, we 
tested this sample along with other borderline and reactive samples by IIFA, rIIF-IgG and 
yielded reactive result. Other reactive samples of the same batch yielded the same ELISA 
result when tested after one year.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8 
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Result of anti MERS-CoV S IgG rELISA for subjects in Qatar. 
 
Sample Source 
 
 
Year of Collection (No. 
screened) 
 
No. Borderline / No. 
Screened (%) 
 
 
No. reactive/ 
No. 
Screened 
(%) 
 
 
Blood Donors 
     
 2012 (120) 1/120 (0.83) 0 (0) 
 2013 (28) 0/28 (0) 0 (0) 
 2014 (611) 0/611 (0) 1/611 (0.16) 
 2015 (3383) 1/3383 (0.03) 5/3383 (0.15) 
 2016 (577) 1/577 (0.17) 1/577 (0.17) 
  
Total (4719) 
 
3/4719 (0.08) 
 
7/4719 (0.13) 
 
Base Line  
Case Contacts  
     
 
 
May.2015 (100) 0/100 (0) 1/100 (1) 
 Feb. 2016 (10) 0/10 (0) 0/10 (0) 
  
June. 2016 (25) 
 
0/25 (0) 
 
0 /25(0) 
 
 
 
Total (135) 
 
0/ 135 (0) 
 
1/ 135 (0.74) 
 
Patients 
     
 Mar. 2015 (1) 0/1 (0) 1/1 (100) 
 May. 2015 (1) 0/1 (0) 1/1 (100) 
 Feb. 2016 (2) * 0/2 (0)  2/2 (100)  
 May. 2016 (1) 0/1 (0) 0/1 (0) 
 
 
 
Total (5) 
 
0/5 (0) 
 
4/5 (80) 
 
All samples 
 
 
Total (4859) 
 
3/4859 (0.06) 
 
12/4859 
(0.25) 
* collected in two different dates (admission and discharge).  
Total number and (percentage) of reactive anti-MERS-CoV IgG by rELISA over the total no. 
screened for each group of the study population. MERS-CoV: middle east respiratory syndrome 
coronaviruses. rELISA: recombinant enzyme linked immunosorbent assay 
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Table 9    
 
 
Evaluation of (A: Borderline, B: Reactive) anti-MERS-CoV rELISA-IgG samples with anti-
MERS-CoV immunoassays & ppNT 
A Borderline rELISA-IgG 
Sample Source 
Year of Collection: No. Borderline/ 
No. Screened (%) 
No. reactive/ No. Screened (%) 
  
Full Virus IIFA-
IgG 
Full Virus IIFA-
IgM 
rIFA-IgG ppNT 
Blood Donors          
2012: 1/120 (0.83) 0/1 (0) 0/1 (0) 0/1 (0) 0/1 (0) 
2015: 1/3383 (0.06) 0/1 (0) 0/1 (0) 0/1 (0) 0/1 (0) 
2016: 1/577 (0.17) 0/1 (0) 0/1 (0) 0/1 (0) 0/1 (0) 
Total: 3  0/3 (0) 0/3 (0) 0/3 (0) 0/3 (0) 
B Reactive rELISA-IgG 
Sample Source 
Year of Collection: No. reactive/ No. 
Screened (%) 
No. Reactive / No. Screened (%) 
  
Full Virus IIFA-
IgG 
Full Virus IIFA-
IgM 
rIIFA-IgG ppNT 
Blood Donors         
2014: 1/611 (0.16) 0/1 (0) 0/1 (0) 0/1 (0) 0/1 (0) 
2015: 5/3383 (0.15) 2/5 (40) 0/5 (0) 0/5 (0) 0/5 (0) 
2016: 1/577 (0.17) 0/1 (0) 0/1 (0) 0/1 (0) 0/1 (0) 
Total: 7 2/7 (28.57) 0/7 (0)  0/7 (0)  0/7 (0)  
 
Base Line Case Contacts  
        
May. 2015: 1/100 (1)  Sample quantity Not sufficient 1/1 (100) 
Total: 1  1/1 (100) 
  
Patients 
       
Mar. 2015: 1/1 (100) 1/1 (100) 0/1 (0) 1/1 (100) 1/1 (100) 
May. 2015: 1/1 (100) 1/1 (100) 0 /1 (0) 1/1 (100) 1/1 (100) 
Feb. 2016: 2/2* 2/2 (100) 1/2 (50) 2/2 (100) 
Test not 
done  
Total: 4 4/4 (100) 1/4 (25) 4/4 (100) 2/2 (100) 
Total: 12 6/11 (54.55) 1/11 (9.09) 
 
4/11 (36.36) 
 
3/11 (27.27) 
* 2 samples for same patient collected in two different dates (admission and discharge).   
Serological findings for A. Borderline and B. Reactive anti-MERS-CoV IgG rELISA samples expressed by total 
number and (percentage) of reactive sample with other MERS-CoV serologic assays over the total no. screened for 
each group of the study population. MERS-CoV: middle east respiratory syndrome coronaviruses. rELISA: 
recombinant enzyme linked immunosorbent assay, IIF: indirect immunofluorescent, rIFA: recombinant 
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immunofluorescent assay, ppNT: pseudoparticle neutralization test.  
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Table 10-A 
 
Serological investigation of reactive anti-MERS IgG rELISA samples 
 
 MERS-CoV 
Full Virus IIFA 
(Titer) 
rELIS
A 
rIIFA (Titer) 
 rELISA IgG 
Full Virus 
IIFA 
rIIFA ppNT 229E SARS HKU1 229E OC43 SARS NL63 HKU1 
Sample 
Identifier 
(OD, Ratio, 
Endpoint Titer) 
IgG 
(Tite
r) 
IgM 
(Titer) 
IgG 
(Titer) 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
D2014/597 
+ 
(0.905, 2.114, 
201) 
0 0 0 < 50 
+ 
(≥ 
320) 
0 
+ 
(≥ 
100) 
+ 
 (320) 
+ 
(320) 
0 
+ 
(3200) 
+ 
(3200) 
D2015/1303 
+ 
(0.397, 1.3, 101) 
+ 
(1000
0) 
0 0 < 50 
+ 
(320) 
0 
+ 
(≥ 
101) 
+ 
(3200) 
+ 
(3200) 
0 
+ 
(3200) 
+ 
 (320) 
D2015/3004 
+ 
(0.439, 1.26, 201) 
0 0 0 < 50 
+ 
(≥ 
1000) 
0 
+ 
(≥ 
101) 
+ 
 (320) 
+ 
(3200) 
0 
+ 
(3200) 
+ 
(3200) 
D2015/3119 
+ 
(0.402, 1.06, 401) 
0 0 0 < 50 
+ 
(≥ 
320) 
0 
+ 
(≥ 
101) 
+ 
 (320) 
+ 
(320) 
0 
+ 
(320) 
+  
(320) 
D2015/3380 
+ 
(0.477, 1.1, 101) 
+ 
(1000
0) 
0 0 < 50 
+ 
(320) 
0 
+ 
(≥ 
101) 
+ 
(3200) 
+ 
(3200) 
0 
+ 
(320) 
+  
(320) 
D2015/3513 
+ 
(0.497, 1.39, 401) 
0 0 0 < 50 
+ 
(≥ 
1000) 
0 
+ 
(≥ 
101) 
+ 
(3200) 
+ 
(3200) 
0 
+ 
(3200) 
+ 
(3200) 
D2015/4435 
+ 
(0.661, 1.74, 201) 
0 0 0 < 50 
+ 
(≥ 
320) 
0 
+ 
(≥ 
101) 
+ 
 (320) 
+ 
(3200) 
0 
+ 
(3200) 
+ 
(3200) 
C/ May.2015 
+ 
(0.61, 1.5, 101) 
Quantity Not Sufficient 
EMC:  76, IC50 
 
 JordanN3: 149, 
IC50 
Quantity Not Sufficient 
P/ March.2015 
+ 
(1.084, 2.86, 201) 
+ 
(1000
0) 
0 
+ 
(˃ 
10000) 
EMC 
  630, IC50/ 184, 
IC80/ 93, IC90 
  
JordanN3 
+ 
(100) 
0 
+ 
(≥ 
101) 
+ 
(320
0) 
+ 
(320) 
+  
(320) 
+ 
 (320) 
+  
(320) 
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1707, IC50/ 206, 
IC80/ 69, IC90 
 
P/ May.2015 
+ 
(0.412, 1.37, *) 
+ 
(3200
) 
0 
+ 
(320) 
EMC:   199, IC50 
 JordanN3: 688, 
IC50 
+ 
(1000) 
0 
+ 
(≥ 
101) 
+ 
(320
0) 
+ 
(3200) 
0 
+ 
 (320) 
+ 
(3200) 
P/ Feb.2016  
(first sample) 
+ 
(0.42, 1.34, 101) 
+ 
(3200
) 
0 
+ 
(3200) 
Not Done 0 0 
+ 
(≥ 
101) 
+ 
(320
0) 
+ 
(˃ 
10000) 
0 0 0 
P/ Feb.2016 
(second sample) 
+ 
(2.229, 6.517, ≥ 
3201) 
+ 
(˃ 
3200
0) 
+ (100) 
+ 
(˃ 
10000) 
Not Done 0 
+ 
(1000) 
+ 
(≥ 
101) 
+ 
(320
0) 
+ 
(˃ 
10000) 
+ (3200) 0 0 
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Table 10-B 
 
Serological investigation of borderline anti-MERS IgG rELISA samples 
 
 
 
 
 
 
  
 MERS-CoV 
Full Virus IIFA 
(Titer) 
rELISA r IIFA (Titer) 
 rELISA IgG Full Virus IIFA r IIFA 
ppN
T 
229E SARS HKU1 229E OC43 SARS NL63 HKU1 
Sample 
Identifier 
(OD, Ratio, Endpoint 
Titer) 
IgG 
(Tite
r) 
IgM 
(Titer) 
IgG 
(Titer) 
(Tite
r) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
D2012/2644 
±  
(0.333, 0.83, 101) 
0 0 0 < 50 
+  
(≥ 1000) 
0 
+ 
(≥ 101) 
+ (320) 
+ 
 (320) 
0 
+  
(320) 
+ (320) 
D2015/1816 
± 
 (0.456, 0.823,201) 
0 0 0 < 50 
+ 
 (≥ 320) 
0 
+ 
(≥ 101) 
+ (3200) 
+ 
 (3200) 
0 + (3200) + (3200) 
D2015/4708 
± 
 (0.408, 1.07, 101) 
0 0 0 < 50 
Not 
Done 
Not 
Done 
+ 
(≥ 101) 
+ (3200) 
+ 
 (3200) 
0 
+  
(320) 
+ (3200) 
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Table 10-C 
 
Serological investigation of selected negative anti-MERS IgG rELISA samples 
 
 MERS-CoV 
Full Virus IIFA 
(Titer) 
rELIS
A 
r IIFA (Titer) 
 rELISA IgG Full Virus IIFA r IIFA ppNT 229E SARS HKU1 229E OC43 SARS NL63 HKU1 
Sample 
Identifier 
(OD, Ratio, 
Endpoint Titer) 
IgG 
(Titer) 
IgM 
(Titer) 
IgG 
(Titer) 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
IgG 
(Titer) 
D2014/469 
- 
(0.027, 0.069, < 
101) 
0 0 0 < 50 Not Done 
Not 
Done 
+  
(≥ 101) 
+  
(320) 
+ 
(3200) 
0 
+ 
(3200) 
+ 
(320) 
D2015/119
0 
- 
(0.033, 0.078, < 
101) 
0 0 0 < 50 Not Done 
Not 
Done 
Not 
Done 
+ 
 (320) 
0 0 
+ 
(320) 
+ 
(3200) 
D2015/122
9 
- 
(0.03, 0.07, < 101) 
0 0 0 < 50 Not Done 
Not 
Done 
Not 
Done 
+ 
 (320) 
+ 
(3200) 
0 
+ 
(3200) 
+ 
(320) 
D2015/161
6 
- 
(0.026, 0.059, < 
101) 
0 0 0 < 50 Not Done 
Not 
Done 
Not 
Done 
+ 
(3200) 
+ 
(3200) 
0 
+ 
(3200) 
+ 
(320) 
D2015/285
9 
- 
(0.034, 0. 076, < 
101) 
0 0 0 < 50 Not Done 
Not 
Done 
Not 
Done 
+ 
(3200) 
+ 
(3200) 
0 
+ 
(3200) 
+ 
(3200) 
D2015/298
8 
- 
(0.039, 0.112, < 
101) 
0 0 0 < 50 Not Done 
Not 
Done 
Not 
Done 
+ 
 (320) 
+  
(320) 
0 0 
+ 
(320) 
D2015/337
9 
- 
(0.065, 0. 16, < 
101) 
0 
+  
(320) 
0 
EMC : 531, 
IC50/ 76, IC80 
 JordanN3 : 502, 
IC50 
+ (320), 
IgM= 0 
0, 
IgM= 0 
Not 
Done 
+ 
(3200) 
+ 
(3200) 
0 
+ 
(320) 
+ 
(320) 
D2015/358
1 
- 
(0.186, 0. 51, < 
101) 
0 0 0 < 50 Not Done 
Not 
Done 
+ 
(≥ 101) 
+  
(320) 
+ (320) 0 
+ 
(320) 
+ 
(3200) 
D2015/374
6 
- 
(0.031, 0.101, < 
101) 
0 0 0 < 50 Not Done 
Not 
Done 
Not 
Done 
+  
(320) 
+ 
(3200) 
0 
+ 
(3200) 
+ 
(3200) 
D2015/389
9 
- 
(0.037, 0. 083, < 
0 0 0 < 50 Not Done 
Not 
Done 
Not 
Done 
+ 
 (320) 
+  
(320) 
0 
+ 
(320) 
+ 
(320) 
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Serological findings for A. Reactive, B. Borderline and C. Negative (randomly selected) anti-MERS-CoV IgG rELISA samples with other serologic method for detection of anti-
MERS-CoV along with serological findings for antibodies to other human coronaviruses. Interpretation of rELISA result as follow Ratio: < 0.8 Negative, ≥ 0.8 - < 1.1 Borderline, 
≥ 1.1 Positive. 
 
 Identifier= D: Donor followed by year of collection then identifier No, C: case Contact, P: patient. MERS: Middle East Respiratory Syndrome, rELISA: recombinant enzyme linked immunosorbent 
assay, IIF: indirect immunofluorescent rIIFA: recombinant indirect immunofluorescent assay, ppNT: pseudoparticle neutralization tests, OD: Optic Density, +: Reactive, ±: borderline, -: Negative, 
229Em OC43, SARS, NL63 ang HKU1: Human coronavirus.  EMC (GenBank JX869059) and Jordan N3 (GenBank KC776174): viral MERS-CoV strains.
101) 
D2015/396
2 
- 
(0.06, 0. 134, < 
101) 
0 0 0 < 50 Not Done 
Not 
Done 
Not 
Done 
+  
(320) 
+ 
 (320) 
0 
+ 
(320) 
+ 
(320) 
D2015/447
2 
- 
(0.189, 0. 409, < 
101) 
0 0 0 < 50 Not Done 
Not 
Done 
+ 
(≥ 101) 
+ 
(3200) 
+ 
(3200) 
0 
+ 
(3200) 
+ 
(3200) 
C/ 
May.2015 
- 
(0.039, 0. 096, < 
101) 
0 0 0 < 50 Not Done 
Not 
Done 
Not 
Done 
+  
(320) 
+  
(320) 
0 0 
+ 
(320) 
P/ 
May.2016  
 
- 
 (0.131, 0. 38, < 
101) 
0 0 0 Not Done 0 0 
Not 
Done 
+  
(320) 
+ 
(3200) 
0 
+  
(320) 
 
0 
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CHAPTER 5: DISCUSSION 
As infection with MERS-CoV continues to evolve, a matter of best infection 
control and management will arise, and studies to better define its prevalence are needed 
because infection control and management recommendations might be reviewed & 
updated as additional data become available.  In the absence of clear epidemiological 
view of MER-CoV, our study   provides an insight about the epidemiological status 
among Qatar population.  It also provides a performance evaluation for the available 
serologic tests for MERS-CoV in a view of serologic status to other human 
coronaviruses.  
 In our investigation, we did not found a significant rate of anti-MERS antibodies 
in samples from blood donors in Qatar through 2012-2016. The actual prevalence of anti-
MERS IgG among Qatar population is difficult to estimate, because our study sampled 
4719 from blood donors only in which the focus on adult male group and few females (77 
vs 4642 male) were included. However, the known predominance of overall reported 
MERS-CoV infection was among male (139) and the low prevalence of anti-MERS-IgG 
among blood donors (0.02 %, 1/4719) detected in our study –confirmed by ppNT-  may 
refer to a similar low prevalence among general population in Qatar, which is also indicated 
by the low number (20 cases) of detected confirmed MERS-CoV infections. Interestingly, 
the low prevalence reported in our study is slightly like a reported prevalence from 
nationwide cross-sectional study in Saudi Arabia. They reported 15 (0.2 %) reactive anti-
MERS-CoV sera collected from 10,009 healthy individuals in 13 provinces in 2012- 2013 
(111). They initially screened sera by rELISA (EUROIMMUN, Germany) and MERS-
CoV seropositivity were confirmed by rIFA and PRNT50 & PRNT90. 
 
   
61 
 Furthermore, the detection of anti-MERS IgM among one of the screened blood 
donors stress the need for further investigation of the possibility of transmission of MERS 
CoV through blood transfusion from asymptomatic patients, though no cases has been 
reported so far with evidence of blood transfusion as source of infection. Additionally, the 
detection of probable (cross reactivity cannot be ruled out) subclinical infections in our 
study supports the believe that the current estimated overall fatality rate associated with 
MERS-CoV infection is most likely overestimated (8). Furthermore, it adds to the concern 
that those subclinical infections may role as an unknown source for spread of infection.  
In term of serological view, our study showed similar results to  Drosten C et al. of 
excess anti-MERS rELISA IgG reactive samples that were not confirmed with IIF-IgG 
assay (129) (8 samples in our study :3 borderline and 5 reactive). These findings suggest 
low specificity of the rELISA IgG test. Further investigations for these potential positive 
samples by rELISA-IgG showed reactive titers against other common human pathogenic 
coronaviruses, further suggesting lower specificity of rELISA test than 
immunofluorescence assay.   
Our results indicate a higher specific reactivity of anti-MERS CoV rIIFA than full 
virus IIFA assay, when compared to the gold standard ppNT assay. Aburizaiza et al. study 
indicates that HKU1-CoV could act as a cause of cross-reactive antigen in the full virus 
anti-MERS IF assay (12) They stated that “despite that immunofluorescence assay is 
considered a highly robust test, the use of whole viral-infected cells immunofluorescence 
assay alone, without a panel of analyses, could result in a portion of false-reactive MERS-
CoV antibody results” (12).  Ours study results suggest that not HKU1-CoV antibody could 
be the source of cross reactivity but also other antibodies to other coronavirus families as 
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our study showed that > 80 % reactive or negative anti-MERS-CoV samples were reactive 
to other human coronaviruses (HCoV-229E, OC43-CoV, NL63) along with HKU1-CoV. 
Thus, crosses reactivity with those coronaviruses cannot be ruled out, though these 
coronaviruses are from different phylogenic groups or/and subgroups than MERS-CoV.  
Our study, collectively with the above discussed studies highlight the importance of 
following the US CDC and WHO strategy of two-phase serological approach of detecting 
anti-MERS antibodies through one screening test such as rELISA, followed by a 
neutralizing confirmatory assay or rIIF (122).  
We reported a failure in detecting anti-MERS CoV-IgG in one of patient 
(confirmed by PCR test) sample included in our study using all rELISA-IgG, IIFT-IgG and 
rIIFA-IgG. However, this sample was not screened with ppNT due to shipping difficulties. 
Yet, reported failure for detection of anti-MERS CoV-IgG is in consistent with previous 
report, where few patients failed to develop a strong antibody response (130). Such findings 
may restrict the use of serologic screening in diagnostic settings as infection may not be 
able to be detected by any of screening serological assays. Furthermore, previous studies 
open a debate of later development and or detection of anti-MERS-IgM than IgG (86, 132). 
In our study, we reported two opposite status. First one was a detection of anti-MERS-IgM 
in blood donor sample (D2015/3379) without detection of anti-MERS-IgG, which may 
indicate earlier development IgM than IgG. Second, two samples were drawn from one of 
our patients (P/ Feb.2016), was drawn at the admission time, and the second one was taken 
just before patient discharge (Table 9 A).  Anti-MERS IgG was detected in both samples 
(P /Feb.2016 first and second samples), however, anti-MERS-COV-IgM was detected only 
the second sample. Thus, the debate is still opened waiting for more concerned study for 
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timeline development of anti-MERS-IgG/IgM and variations of the immunoglobulin class-
specific serologic assays. 
The detection of anti-SARS- CoV IgG in 2 samples collected from 2 confirmed 
MERS-CoV patients by IIFT and/ or r-IIFA is consistent with previous reports (83, 88).  
Additionally, this study questions the ability of rELISA-IgG for detection of anti-
MERS IgG in serum samples stored frozen (-70 0C) for one year. The Negative anti-MERS-
IgG rELISA patient sample after one year of reactive result for the same sample may 
restrict the screening utility using the same ELISA method used in our study for long shelf 
(> one year) stored samples. However, one sample result conflict is not enough to 
implement such restriction and further studies should be conducting before draw such 
conclusion particularly, when keeping in consideration that the conflict in the result with 
period may resulted from improper handling or storage specifically for that sample. 
The base line investigation of case contacts in our study is of limited value as we 
were not able to collect further samples after 2 weeks of exposure to check for 
seroconversion. However, detecting of one reactive anti-MERS-IgG among one of the 
traced case contact, value the WHO recommendations of active survey of case contacts 
following confirmation of MERS CoV human infection. Yet, our reactive anti-MERS IgG 
samples, which was confirmed by ppNT, need a follow up investigations i.e. anti-MERS 
IgM and PCR, which may indicate the current stage of the subject and rule out cross 
reactivity. Additionally, the presence of anti-MERS-CoV IgG and neutralizing antibodies 
at the time of baseline surveillance rise the question that this subject could be the case index 
rather than case contact. 
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CHAPTER 6: CONCLUSION 
Our findings suggest that MERS-CoV is not heavily circulated among the 
population of Qatar. Additionally, the presence of antibody of other pathogenic human 
coronavirus may cause false positive results of both rELISA and IIFT (full virus), which 
stress the need for more evaluation studies for the available serological assays. This study 
provides an insight about the epidemiological view for MERS-CoV in Qatar population. 
It also provides a performance evaluation for the available serologic tests for MERS-CoV 
in a view of serologic status to other human coronaviruses.  
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FUTURE PERSPECTIVES 
 
Though our knowledge about MERS-CoV has been expanded over the last years, 
yet, the human serologic response to MERS-CoV infection and seroconversion of 
infected individuals is not fully covered and understood. Few studies addressed the 
antibody response to MERS-CoV infection and its correlate to the severity of the disease 
(127, 130, 132). Additionally, limited studies followed the longevity of the antibodies 
response and its correlate to the initial severity of the infection (129, 140, 141). The 
findings of studies following patients’ antibody response may impact the understanding 
of the pathogenesis of MERS-CoV infection and hold the promise for a better treatment 
and management of the diseases.  Thus, further studies of human antibody response to 
MERS-CoV infection are of our priority for research studies.  
Though our study mainly aimed to provide an insight for the epidemiological 
view for MERS-CoV in Qatar population, the enriched results of various serologic assays 
in our study trigger us to fatherly correlate serologic assays –used in this study- and 
compare it with published data. This perspective will be conducted upon including more 
reactive samples. 
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